newsfilter
← Latest News
GlobeNewswire·

Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial

STS101 demonstrated a favorable safety and tolerability profile, consistent with clinical experience to date Over 8,000 migraine attacks treated with more than 10,000 doses of STS101; of which, over 5,500 migraine attacks treated with more than 6,900 d